Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 229

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 229
---
,620 | ) |

General and Administrative Expenses

General and administrative
expenses were $2.6 million for the three-month period ended September 30, 2024 compared to $0.3 million for the three-month period ended
September 30, 2023, reflecting an increase of $2.4 million. The increase in the three-month period ended September 30, 2024, over the
three-month period ended September 30, 2023, was predominantly due to the expenses associated with operating as a publicly traded company.
The hiring of senior management in G&A resulted in an increase of $0.2 million in the three-month period ended September 30, 2024,
versus the three-month period ended September 30, 2023, and expenses associated with public company filings and financings increased
legal expenses $1.0 million, and accounting and filing-associated expenses $0.2 million in the three-month period ended September 30,
2024, versus the three-month period ended September 30, 2023. Business consulting services and directors’ fees increased $0.5 million
in the three-month period ended September 30, 2024, versus the three-month period ended September 30, 2023. Public company insurance
coverage increased insurance expenses $0.1 million in the three-month period ended September 30, 2024, versus the three-month period
ended September 30, 2023. Other expenses, including corporate communication expenses, recruiting expenses, IT expenses, and travel costs
increased $0.1 million in the three-month period ended September 30, 2024, versus the three-month period ended September 30, 2023.

Research and Development Expenses

Research and development
expenses were $1.8 million for the three-month period ended September 30, 2024 compared to $1.3 million for the three-month period ended
September 30, 2023, reflecting an increase of $0.5 million. The increase was related to increased research and development activity as
the Company addressed regulatory questions related to the IND for CER-1236 and prepared for the clinical trial, anticipated to start
after the clinical hold for CER-1236 is lifted. Clinical expenses increased $0.2 million, manufacturing increased by $0.1 million and
research and development consulting increased by $0.3 million, offset by a reduction of $0.2 million in compensation expenses and the